Some calls about some things... This must be “International Phone Somebody Week” because I've been continuously on the phone since early Monday morning.
So what are the calls about? No news, that’s one thing. Well, there was some news, important news, news about siRNA and stroke that in the end convinced Aposense that they'd best do some work with Bioasis to see how xB3 might be used with some of their siRNA properties. In other words, people smarter than you and I think they'd best put some of their financial, physical and personnel resources to work on xB3. That's pretty good stuff, right there.
And then people are worried about the missed data deadline. For the most part, though, they understand that when somebody else is doing the work that produces the data, then Bioasis is dependent on them for delivery of the data. It's not in Bioasis' hands. I think there is disappointment but also some reluctant understanding.
The thing that caused me the most grief from shareholders yesterday and today is that the corporate presentation (CP) still has the Q1 CY2021 data delivery predictions on it. Sorry folks. I cannot explain that one. Not even going to try. The company needs to edit page 4 of that document. Make another prediction or remove the prediction.
But, folks, it's a pretty small matter. It will get fixed, I'm sure.
And about the share price, up and down, whatever, it's just market noise. Do you think Chiesi looks at the Bioasis share price? Nooooo! They've put their money down to get four enzymes into the brains of LSD sufferers. They have the knowledge to size up xB3 and they want it.
XOMA wanted it too. They put US$1.2 million down to pick up a small piece of the milestones and eventual drug sales. They didn't phone up Stockhouse posters to see if it was a wise thing to do. They have actual scientists to assess these things. And they chose to exercise the option.
Aposense has the sense to understand that a yoyo with no string will stay in the toy box. They have siRNA properties, and maybe more importantly, opportunities with new but not yet created siRNA therapies that, without transport into the brain, will never see the light of day. This is a big opportunity for Aposense and they completely understand that. They, also, will be using their financial, physical and financial resources to get stuff done with xB3. Money on the line and some shareholders whined that no money traded hands. I’ll have more to say about Aposense and related things before long.
You know, it may be time for some of you to sell this stock if you can't or won't even try to understand what you own. It's one thing that you're a nuisance to other shareholders. It's an entirely other thing that your own mental health may be an issue because of what you believe or refuse to believe about Bioasis.
But the rest of us are going be here. We have trust in the Chiesi, XOMA, Prothena, Aposense and other scientists who understand the opportunities presented by xB3. They understand the science and they know the commercial cases that can be made for xB3, and that's why they signed up.
So, should these companies and their scientists be monitoring this forum so see whether they might have missed something important about xB3 and Bioasis?
Yeah, no, not hardly likely.
jd